Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer

StatusActive, Not Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Jul 2026 → Jul 2027
See other at-risk trials from Memorial Sloan Kettering Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 2026 to Jul 2027
    • Eligibility criteria expanded, about 10 words
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 9
    • Site details revised
    v16
  3. Eligibility criteria expanded, about 6 wordsv15
  4. 2 versions Re-verified since Jul 19, 2024, no change to tracked fieldsv13-v14
  5. Primary and study completion dates: Nov 2023 to Jul 2026v12
Show 10 earlier versionsHide 10 earlier versions
  1. 2 versions Re-verified since Nov 8, 2022, no change to tracked fieldsv10-v11
  2. Site contact updatedv9
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2022 to Jul 13, 2022
    • Site details revised
    v8
  4. Start date: May 2022 to Jul 2022v7
  5. Start date: Apr 2022 to May 2022v6
  6. Start date: Mar 2022 to Apr 2022v5
  7. Start date: Feb 2022 to Mar 2022v4
  8. Start date: Dec 2021 to Feb 2022v3
  9. Start date: Nov 2021 to Dec 2021v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The researchers doing this study think that performing scans of the brain and testing cerebrospinal fluid (CSF) in people with HER2-positive breast cancer may be an effective way of identifying the early onset of CNS metastases (such as brain cancer). If the researchers can identify the early onset of CNS metastases, they can immediately treat that cancer and possibly prevent it from worsening. Currently, people with breast cancer don't usually have scans of the brain or CSF testing unless they are experiencing symptoms of CNS metastases.
Trial Details
NCT Number NCT05130840
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov